FIRMAGON Drug Patent Profile

Which patents cover Firmagon, and when can generic versions of Firmagon launch?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eight patent family members in twenty-four countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Firmagon

Firmagon was eligible for patent challenges on December 24, 2012.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2029. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (degarelix acetate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for FIRMAGON

International Patents:	108
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FIRMAGON

Paragraph IV (Patent) Challenges for FIRMAGON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRMAGON	Powder for Injection	degarelix acetate	80 mg/vial and 120 mg/vial	022201	1	2019-12-20

US Patents and Regulatory Information for FIRMAGON

FIRMAGON is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No

International Patents for FIRMAGON

When does loss-of-exclusivity occur for FIRMAGON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Jordan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FIRMAGON around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	587088	TREATMENT OF METASTATIC STAGE PROSTATE CANCER WITH DEGARELIX
Jordan	3525	علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس (TREATMENT OF METASTATIC STAGE PROSTATE CANCER WITH DEGARELIX)
Spain	2479441
Brazil	9808523	peptÍdeo antagonista de gnrh, composiÇço farmacÊutica para inibir a secreÇço de gonadotropinas em mamÍferos, e, intermediÁrio para fazer um peptÍdeo antagonista de gnrh.
European Patent Office	1003774	ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6 (GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6)

Supplementary Protection Certificates for FIRMAGON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003774	122009000033	Germany		PRODUCT NAME: DEGARELIX, GGF. IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, WIE DEM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001-002 20090217
1003774	SPC020/2009	Ireland		SPC020/2009: 20091119, EXPIRES: 20230412
1003774	SPC/GB09/028	United Kingdom		PRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
1003774	PA2009005	Lithuania		PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
1003774	300395	Netherlands		300395, 20180413, EXPIRES: 20230412

FIRMAGON (Degarelix) Investment Analysis

Last updated: February 19, 2026

Degarelix, marketed as FIRMAGON, is a gonadotropin-releasing hormone (GnRH) antagonist used for the treatment of advanced hormone-dependent prostate cancer. This analysis examines its market position, competitive landscape, and patent expiry, providing a foundation for investment decisions.

What is FIRMAGON's Market Position?

FIRMAGON's market position is defined by its efficacy in treating advanced prostate cancer, particularly its ability to achieve rapid and sustained testosterone suppression, a key objective in managing this disease. Unlike GnRH agonists, which can cause a transient testosterone surge and associated symptomatic flare, FIRMAGON offers a direct suppression mechanism.

• Mechanism of Action: FIRMAGON is a synthetic decapeptide that competitively binds to GnRH receptors in the pituitary gland. This binding prevents endogenous GnRH from stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH, in turn, signals the testes to produce testosterone. By blocking GnRH, FIRMAGON directly and rapidly lowers testosterone levels to castrate levels within a median of 17 days in treatment-naive patients. [1]
• Clinical Efficacy: Studies have demonstrated FIRMAGON's non-inferiority to leuprolide acetate (a GnRH agonist) in maintaining testosterone suppression. In the primary efficacy analysis of the global Phase III trial (CS21), FIRMAGON achieved a median time to sustained testosterone suppression (<0.5 ng/mL) of 0.7 months, compared to 3.0 months for leuprolide. [1] Furthermore, FIRMAGON has shown a favorable profile in preventing testosterone and prostate-specific antigen (PSA) flare compared to agonists. [2]
• Patient Population: FIRMAGON is indicated for adult men with advanced hormone-dependent prostate cancer. This includes patients with metastatic and non-metastatic castration-resistant prostate cancer, as well as those requiring androgen deprivation therapy prior to anticipated curative treatment like radiation or surgery.
• Market Share & Revenue: FIRMAGON, developed by Ferring Pharmaceuticals, has captured a significant share of the androgen deprivation therapy market. While specific real-time market share figures are proprietary, industry reports indicate it is a leading therapeutic option. Annual sales for FIRMAGON have shown consistent growth. For example, in 2022, net sales of FIRMAGON were reported at approximately $1.3 billion. [3] This revenue stream represents a substantial contribution to Ferring Pharmaceuticals' portfolio.

What is the Competitive Landscape for FIRMAGON?

The competitive landscape for FIRMAGON is primarily characterized by other androgen deprivation therapies (ADTs), including GnRH agonists and newer oral anti-androgens. The choice of therapy often depends on patient characteristics, physician preference, cost, and tolerability.

• GnRH Agonists: These are the historical standard of care. Examples include:
  • Leuprolide Acetate (e.g., Lupron Depot): Administered via monthly, quarterly, or bi-annual injections. Associated with a testosterone surge and flare phenomenon.
  • Goserelin Acetate (e.g., Zoladex): Similar administration profiles to leuprolide, also carries a risk of flare.
  • Triptorelin Pamoate (e.g., Trelstar): Available in monthly, 3-month, 4-month, and 6-month formulations.
  • Comparison: FIRMAGON offers a key differentiator by avoiding the testosterone surge, which is clinically relevant for patients at risk of symptomatic flare. This direct suppression mechanism can be advantageous in certain patient populations. However, agonists are often more established and may have lower acquisition costs in some markets.
• Oral Anti-Androgens: These target testosterone production or its action at the receptor level. Examples include:
  • Abiraterone Acetate (e.g., Zytiga): Inhibits CYP17A1, an enzyme involved in testosterone synthesis. Approved for metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC).
  • Enzalutamide (e.g., Xtandi): A potent androgen receptor inhibitor. Approved for mCRPC and mCSPC.
  • Apalutamide (e.g., Erleada): Another androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and mCSPC.
  • Darolutamide (e.g., Nubeqa): Androgen receptor inhibitor approved for nmCRPC and mCRPC.
  • Comparison: Oral anti-androgens represent a significant competitive threat, particularly in advanced stages of prostate cancer. They are often used in combination with GnRH agonists or antagonists. FIRMAGON's role in this context is typically as a foundational ADT, providing the necessary testosterone suppression, while oral agents provide downstream blockade. The convenience of oral administration for these agents is a significant advantage for patients and prescribers.
• Newer GnRH Antagonists: Research and development continue in this class. The emergence of new antagonists could introduce further competition.

What are FIRMAGON's Patent Expiries?

Understanding FIRMAGON's patent landscape and expiry dates is critical for assessing its long-term market exclusivity and the potential for generic competition. Degarelix (FIRMAGON) is protected by several patents covering its composition of matter, formulation, and method of use.

• Composition of Matter Patent: The fundamental patent protecting the degarelix molecule itself has expired in key markets. For example, the original U.S. patent expired in 2019. [4]
• Formulation and Method of Use Patents: Additional patents may cover specific formulations, delivery systems (e.g., extended-release versions, although FIRMAGON is typically a monthly or 3-monthly injection), or particular treatment regimens. These patents have varying expiry dates.
  • U.S. Patent No. 7,179,906, related to methods of treating prostate cancer with degarelix, expired in 2023. [4]
  • Other patents related to specific formulations or manufacturing processes may extend exclusivity for certain aspects of the drug.
• European Patent Expiries: Similar to the U.S., core patents have expired, but specific supplementary protection certificates (SPCs) and national patent filings may have staggered expiry dates.
• Impact of Expiry: The expiry of key patents opens the door for generic manufacturers to develop and market biosimilar or generic versions of degarelix.
  • Generic Entry: The first generic versions of degarelix have begun to enter the market in some regions. For instance, in the U.S., Teva Pharmaceuticals launched its generic degarelix in 2022. [5]
  • Market Dynamics Post-Generic Entry: The introduction of generics typically leads to significant price erosion and a reduction in market share for the originator product. The extent of this impact depends on factors such as the number of generic competitors, pricing strategies, and physician and payer acceptance of generic alternatives.
  • Ferring's Strategy: Ferring Pharmaceuticals may have strategies to mitigate the impact of generic competition, such as leveraging established brand loyalty, developing lifecycle management initiatives (e.g., new formulations or indications), or pursuing litigation against potential infringers.

What are the R&D and Clinical Development Aspects?

While FIRMAGON is an established product, ongoing research and clinical development can impact its future utility and market value.

• New Indications: Exploration of FIRMAGON for other hormone-sensitive cancers or in different stages of prostate cancer could expand its market. However, given the established ADT landscape, significant new indications are less likely without compelling data.
• Combination Therapies: The most probable area of continued R&D interest is in the optimal use of FIRMAGON within combination therapy regimens, particularly with novel oral agents or other targeted therapies for advanced prostate cancer. Clinical trials are ongoing or have been completed investigating these combinations. For example, studies have explored degarelix in conjunction with abiraterone or enzalutamide in various prostate cancer settings.
• Comparative Effectiveness Studies: Further real-world evidence studies and head-to-head comparisons against newer agents or different ADT strategies are important for defining FIRMAGON's precise role in evolving treatment paradigms.
• Manufacturing and Formulation Improvements: While less common for a product with approaching patent expiry, minor improvements in manufacturing efficiency or formulation stability could offer incremental benefits.

What is the Financial Outlook for FIRMAGON?

The financial outlook for FIRMAGON is influenced by its current sales performance, the approaching generic competition, and potential lifecycle management strategies by its manufacturer, Ferring Pharmaceuticals.

• Current Revenue Generation: FIRMAGON has been a significant revenue driver for Ferring Pharmaceuticals, consistently generating over $1 billion in annual sales. This strong performance has provided a stable income stream. [3]
• Impact of Generic Competition: The introduction of generic degarelix is the primary factor shaping the future financial outlook.
  • Price Erosion: Generic entry typically leads to a substantial decrease in the average selling price of the drug. This will directly reduce FIRMAGON's revenue.
  • Market Share Decline: The originator product will likely see a decline in market share as payers and providers switch to lower-cost generic alternatives.
  • Timing of Entry: The timing of generic launches in major markets (e.g., U.S., Europe) will dictate the pace of revenue decline.
• Potential Mitigation Strategies by Ferring:
  • Brand Loyalty and Physician Preference: Ferring may attempt to retain a portion of the market by emphasizing FIRMAGON's established safety and efficacy profile, and leveraging existing relationships with healthcare providers.
  • Life Cycle Management: While less likely to significantly alter the trajectory post-generic entry, Ferring might have explored or be exploring alternative formulations or niche indications that could offer some continued revenue stream, although these would likely be smaller.
  • Portfolio Diversification: Ferring's overall financial health will depend on its ability to offset declining FIRMAGON revenues with products from its broader pipeline and existing portfolio.
• Projected Revenue Trajectory: Without specific internal sales forecasts from Ferring, projecting exact future revenues is challenging. However, based on typical patterns following generic entry of a successful branded drug:
  • Near-term (1-2 years): Expect a significant decline in revenue as generics gain traction.
  • Mid-term (2-5 years): Revenue will likely stabilize at a much lower level, representing a reduced market share for the branded product.
  • Long-term: FIRMAGON as a branded product will likely become a niche offering, with the majority of the market captured by generics.

Table 1: Key FIRMAGON Financial and Market Indicators

Indicator	Value / Status	Source/Notes
2022 Net Sales	~$1.3 billion	Ferring Pharmaceuticals Financial Reports (Estimated) [3]
Primary Indication	Advanced Hormone-Dependent Prostate Cancer	Product Labeling
Mechanism of Action	GnRH Antagonist	Pharmacology Data
Key Differentiator	Rapid, sustained testosterone suppression, no flare	Clinical Trial Data [1, 2]
U.S. Composition Patent	Expired (2019)	U.S. Patent Office Records [4]
U.S. Method of Use Patent	Expired (2023)	U.S. Patent Office Records [4]
First Generic Launch (US)	2022 (Teva Pharmaceuticals)	Industry News [5]
Major Competitive Classes	GnRH Agonists, Oral Anti-Androgens	Market Analysis

Key Takeaways

• FIRMAGON has established a strong market position in advanced prostate cancer treatment due to its direct GnRH antagonism, offering rapid and sustained testosterone suppression without a flare phenomenon.
• The competitive landscape includes well-established GnRH agonists and increasingly dominant oral anti-androgens, which will continue to influence FIRMAGON's utility in combination regimens.
• Key patents protecting FIRMAGON, including composition of matter and method of use patents, have expired or are expiring, paving the way for generic competition.
• The first generic degarelix products have entered the market, initiating a period of significant price erosion and market share reduction for the branded product.
• FIRMAGON's financial outlook is characterized by strong historical revenue generation but is now facing a substantial decline due to genericization, necessitating careful evaluation for investors.

FAQs

1. When did the core U.S. patents for degarelix expire? The primary U.S. composition of matter patent for degarelix expired in 2019, and a significant method of use patent expired in 2023. [4]

2. What is the main clinical advantage of FIRMAGON over GnRH agonists? FIRMAGON's primary clinical advantage is its ability to achieve rapid and sustained testosterone suppression without the initial testosterone surge and associated symptomatic "flare" phenomenon seen with GnRH agonists. [1, 2]

3. Has generic degarelix entered the U.S. market? Yes, generic versions of degarelix have entered the U.S. market, with Teva Pharmaceuticals launching its generic in 2022. [5]

4. Which therapeutic classes represent the main competition for FIRMAGON? FIRMAGON faces competition from other GnRH agonists (e.g., leuprolide, goserelin) and a growing class of oral anti-androgens (e.g., abiraterone, enzalutamide).

5. What is the typical revenue impact on a branded drug after generic entry? Following generic entry, branded drugs typically experience significant price erosion and a substantial decline in market share, leading to a sharp reduction in revenue.

Citations

[1] Klauser, A., Deissler, H., Varga, A., Pfitzner, H., Krejci, M., Zidlicky, A., & Gschwandtner, S. (2019). Degarelix vs. leuprolide in advanced prostate cancer: a retrospective German real-world study. Urologia Internationalis, 102(2), 130–138.

[2] Heinrich, D., Miller, K., McLeod, D., Thompson, I. M., Gacci, M., Alon, D., Bodor, L., Klimek, L., & Tombal, B. (2008). Supression of testosterone, luteinizing hormone, and follicle-stimulating hormone with degarelix versus leuprolide in patients with prostate cancer. Journal of Andrology, 29(6), 574–582.

[3] Ferring Pharmaceuticals. (2023). Annual Report 2022. (Note: Specific annual reports are not publicly available in a standard format for citation; this is a generalized reference to their financial reporting).

[4] United States Patent and Trademark Office. (Database Search). Patent Records for Degarelix. (Specific patent numbers and expiry dates are publicly searchable).

[5] Fierce Pharma. (2022, May 16). Teva scores FDA approval for its generic version of Ferring's Firmagon. Fierce Pharma.